Glycan quality control in and out of the endoplasmic reticulum of mammalian cells

• Published in: The FEBS journal 2022-11, Vol.289 (22), p.7147-7162
• Main Authors: Harada, Yoichiro, Ohkawa, Yuki, Maeda, Kento, Taniguchi, Naoyuki
• Format: Article
• Language: English
• Subjects: Animals; asparagine‐linked glycosylation; Biosynthesis; carbohydrate metabolism; Carbohydrates; Cell death; Cell viability; Cellular stress response; Congenital anomalies; congenital disorders of glycosylation; Control systems; dolichol‐linked oligosaccharides; Embryogenesis; Embryonic growth stage; Endoplasmic reticulum; Endoplasmic Reticulum - metabolism; Glycan; Glycoproteins; Glycoproteins - metabolism; Glycosylation; Mammalian cells; Mammals; Mammals - metabolism; nucleotide sugars; Polysaccharides; Polysaccharides - metabolism; Protein folding; Proteins; Quality Control; Risk reduction; Tumors
• ISSN: 1742-464X; 1742-4658
• DOI: 10.1111/febs.16185

The endoplasmic reticulum (ER) is equipped with multiple quality control systems (QCS) that are necessary for shaping the glycoproteome of eukaryotic cells. These systems facilitate the productive folding of glycoproteins, eliminate defective products, and function as effectors to evoke cellular signaling in response to various cellular stresses. These ER functions largely depend on glycans, which contain sugar‐based codes that, when needed, function to recruit carbohydrate‐binding proteins that determine the fate of glycoproteins. To ensure their functionality, the biosynthesis of such glycans is therefore strictly monitored by a system that selectively degrades structurally defective glycans before adding them to proteins. This system, which is referred to as the glycan QCS, serves as a mechanism to reduce the risk of abnormal glycosylation under conditions where glycan biosynthesis is genetically or metabolically stalled. On the other hand, glycan QCS increases the risk of global hypoglycosylation by limiting glycan availability, which can lead to protein misfolding and the activation of unfolded protein response to maintaining cell viability or to initiate cell death programs. This review summarizes the current state of our knowledge of the mechanisms underlying glycan QCS in mammals and its physiological and pathological roles in embryogenesis, tumor progression, and congenital disorders associated with abnormal glycosylation. The biosynthesis of asparagine‐linked glycans is strictly monitored by a system that selectively degrades structurally defective glycans before adding them to proteins in the endoplasmic reticulum. This novel cellular system, which is referred to as the glycan quality control system (QCS), has a dual role in maintaining and disrupting ER homeostasis. We here discuss how these two opposite functions of the glycan QCS can be cell context‐dependent and determined by genetic and environmental factors.